Washington, D.C. – The Medical Imaging & Technology Alliance (MITA), the Council on Radionuclides and Radiopharmaceuticals (CORAR) Inc., and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) today announced that 123 organizations have expressed their support for the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2023 (H.R. 1199/S. 1544). Support for the FIND Act of 2023 comes from a diverse range of organizations, including patient advocacy groups, medical societies, and industry leaders. The legislation is also being considered tomorrow in a House Energy & Commerce Health Subcommittee hearing on improving seniors’ access to innovative drugs, medical devices, and technology.

Diagnostic radiopharmaceuticals enable clinicians to diagnose and treat a wide variety of life-threatening conditions, such as Alzheimer’s & Parkinson’s disease, breast & prostate cancer, heart disease, and neuroendocrine tumors. Unfortunately, Medicare currently bundles payments for this life-saving technology, creating access barriers for patients who need nuclear medicine procedures.

"It’s thrilling to see such widespread support for the FIND Act of 2023," said Patrick Hope, Executive Director of MITA. "This legislation will help ensure that more patients have access to the latest nuclear medicine innovations and technologies."

"We are proud to stand alongside more than 100 organizations in support of the FIND Act, which will help ensure that patients have access to the latest diagnostic nuclear medicine procedures and technologies,” said Helen Nadel, President of the SNMMI.

“With over 100 organizations pledging their support, we continue to build momentum behind improving access to these life-saving technologies for all patients,” said Michael J. Guastella, Executive Director of CORAR. “We look forward to continuing to work alongside lawmakers to improve access through passage of this legislation.”

“When it comes to prostate cancer, men deserve innovative testing and imaging diagnostics for an accurate diagnosis and informed evaluation of disease progression and treatment efficiency,” said Ali Manson, Vice President of Government Relations and Advocacy for ZERO Prostate Cancer. “It is time for Congress to expand access to these procedures and address flawed payment policy through passage of the FIND Act.”

The full list of supporters includes:

AdMeTech Foundation
Advanced Accelerator Applications/Novartis
Aimed Alliance
Alamo Breast Cancer Foundation
Alliance for Aging Research
Alliance for Patient Access
Alpha-1 Foundation
Alzheimer’s Association
Alzheimer’s Los Angeles
American Behcet’s Disease Association
American Brain Coalition
American College of Nuclear Medicine
American College of Radiology
American Parkinson Disease Association
American Society of Radiologic Technologists
American Society of Neuroradiology
AnCan Foundation
Arizona Prostate Cancer Coalition, Inc.
Autoimmune Association
Avery’s Hope
Best Day Ever Foundation
Biogen
Blue Earth Diagnostics
Bracco Diagnostics
Brian Grant Foundation
Cancer ABCs
Carcinoid Cancer Foundation
Cardinal Health
Center for Medicine in the Public Interest
Cervivor
Clarity Pharmaceuticals
Colorectal Cancer Alliance
Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR)
Curium
Dallas Area Parkinson Society
Davis Phinney Foundation
Diabetes Leadership Council
Diabetes Patient Advocacy Coalition
Eckert & Ziegler Isotope Products
Eckert & Ziegler Radiopharma, Inc.
Eden Radioisotopes, LLC
Eli Lilly & Co.
Eisai
Friends of Parkinson’s
FORCE: Facing Hereditary Cancer Empowered
GE HealthCare
GO2 Foundation for Lung Cancer
Hawai’i Parkinson Association
Healing NET Foundation
Houston Area Parkinson Society
ICAN, International Cancer Advocacy Network
Infusion Providers Alliance
International Isotopes, Inc.
Ionetix
ITM USA, Inc.
Jubilant Radiopharma
Learn Advocate Connect: A Neuroendocrine Tumor Society
Lantheus Holdings, Inc.
Lewy Body Dementia Association
Life Molecular Imaging (Formerly Piramal
Lobular Breast Cancer Alliance
Looms for Lupus
Los Angeles Carcinoid Neuroendocrine Tumor Society
LUNGevity
Mayo Clinic Department of Radiology
Medical Imaging &Technology Alliance (MITA)
MedTrace
METAvivor
Michael J. Fox Foundation for Parkinson’s Research
Michigan Parkinson’s Foundation
North American Neuroendocrine Tumor Society (NANETS)
National Alliance for Caregiving
National Alliance of State Prostate Cancer Coalitions
National Association of Nuclear Pharmacies
National Minority Quality Forum
Navidea Biopharmaceuticals
Neuroendocrine Tumor Research Foundation
NorCal CarciNET Community
Northern California PET
NorthStar Medical Technologies, LLC
Northwest Parkinson’s Foundation
One Cancer Place
Optimal Tracers
Parkinson Association of Alabama
Parkinson Association of the Carolinas
Parkinson Association of Central Florida
Parkinson Association of Northern California
Parkinson Association of the Rockies
Parkinson’s Foundation
Parkinson’s Resources of Oregon
Parkinson & Movement Disorder Alliance
Parkinson Voice Project
Patient Empowerment Network
PD Avengers
People with Empathy
PharmaLogic
Pheo Para Alliance
Power for Parkinson’s
Power over Parkinson’s
Practicing Physicians of America
Prostate Conditions Education Council
Prostate Health Education Network
Rare Access Action Project
RetireSafe
Right Scan Right Time
SHINE Medical Technologies
Siemens Healthineers
Society of Nuclear Medicine & Molecular Imaging (SNMMI)
SOFIE
Sun Pharmaceutical Industries, Inc.
SYNGAP1 Foundation
SSADH Association
Support for People with Oral Head and Neck Cancer (SPOHNC)
Telix Pharmaceuticals, Inc.
TerraPower Isotopes
Texas Rare Alliance
ThyCa: Thyroid Cancer Survivors’ Association, Inc.
Upequity
Veterans Prostate Cancer Awareness Inc.
Voices of Alzheimer’s
Wisconsin Rare Disease Alliance
Young Survival Coalition
ZERO Prostate Cancer

U.S. Healthcare Homepage